Near-infrared photoimmunotherapy
Can near-infrared photoimmunotherapy achieve reliable local control of solid cancers in people?
Following this Track shows whether a treatment approach discussed in reviews for solid cancers advances from potential applications to verifiable human evidence. That evidence could clarify how much confidence to place in its promise for local tumor control.
Where it stands now
Main bottleneck
The supplied trajectory consists of reviews discussing challenges, potential, and recent progress; it does not establish whether NIR-PIT reliably controls solid cancers in human applications.
Watch next
A verifiable human study reporting treatment safety and local tumor-control outcomes for a defined solid cancer.
Progress timeline
How the evidence has changed over time.
2023 · 1 update
- Could treating one tumor with light affect cancer elsewhere?Partly supportedResearch note 3 of 3 · Source date 2023-01-31
Since the previous research note · Partly supported
Track continuity
Since the previous research note: How light-activated cancer treatment works and what limits its wider use
Previous expectation: Bringing targeted light through a scope or into a treatment field might extend local care to tumors external light cannot reach, if delivery proves safe and beneficial.
What this study adds: The 2023 review describes internal light-delivery approaches and cites reduced tumor growth with a catheter in mouse xenografts, while broadening the track’s focus to targeting and immune effects. It does not establish better outcomes for patients with deeper tumors or test the proposed surgical-field use.
Current research note
2022 · 1 update
- How light-activated cancer treatment works and what limits its wider usePartly supportedResearch note 2 of 3 · Source date 2022-10-09
Since the previous research note · Partly supported
Track continuity
Since the previous research note: Why did light-activated treatment slow some bladder tumors in mice but not others?
Previous expectation: Targeted light might one day help control cancer left near a difficult surgical margin if targeting, illumination and safety hold up in people.
What this study adds: The 2022 review cites reduced regrowth in a postsurgical mouse model, although every treated mouse eventually had recurrence. It separately summarizes head and neck human studies and Japan’s 2020 approval for specified unresectable or recurrent disease.
Current research note
2021 · 1 update
- Why did light-activated treatment slow some bladder tumors in mice but not others?Research note 1 of 3 · Source date 2021-04-06
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.